Ann-Kathrin Eisfeld | Molecular Profiles | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Ann-Kathrin Eisfeld | Molecular Profiles | Best Researcher Award

The Ohio State University | United States

Dr. Ann-Kathrin Eisfeld is an internationally recognized physician-scientist and Associate Professor with Tenure in the Division of Hematology at The Ohio State University, where she also serves as Director of the Clara D. Bloomfield Center for Leukemia Outcomes Research. Her research focuses on the molecular and genetic underpinnings of acute myeloid leukemia (AML), with a particular emphasis on translational applications that improve patient outcomes. Dr. Eisfeld has published extensively in high-impact journals such as Nature, Leukemia, Blood, and Cell Stem Cell, contributing significantly to our understanding of leukemia biology, clonal evolution, and treatment resistance. she has authored over 100 peer-reviewed scientific publications, with an h-index of 38, more than 6,500 citations, and has led or co-led multiple collaborative studies within national consortia such as the Alliance for Clinical Trials in Oncology. Her work has identified critical biomarkers and therapeutic targets in AML, including insights into TP53 mutations, FLT3 alterations, and resistance mechanisms to venetoclax. Recognized for her integration of clinical insight with cutting-edge genomics, Dr. Eisfeld is a leading voice in precision oncology and leukemia research, shaping the future of individualized treatment strategies through both clinical innovation and scientific discovery.

Profile: Scopus

Featured Publications:

“Highly elevated serum hepcidin in patients with acute myeloid leukemia prior to and after allogeneic hematopoietic cell transplantation: Does this protect from excessive parenchymal iron loading?”

“Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia”

“miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia”

“Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia”

“Kinetics of iron removal by phlebotomy in patients with iron overload after allogeneic hematopoietic cell transplantation”

“inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations”

“Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients”

“In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline”

“A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia”

Hannah Wen | Breast Cancer | Best Researcher Award

Published on by Cell Biologist

Dr. Hannah Wen | Breast Cancer | Best Researcher Award

Dr. Hannah Wen, MEMORIAL SLOAN KETTERING CANCER CENTER, United States

Dr. Hannah Y. Wen, M.D., Ph.D., is a distinguished breast cancer pathologist and cancer researcher at Memorial Sloan Kettering Cancer Center (MSKCC) in New York. With dual training in medicine and cancer biology, Dr. Wen’s career reflects a deep commitment to advancing the field of translational oncology. Her research focuses on triple-negative breast cancer (TNBC), rare breast tumor subtypes, and predictive/prognostic biomarkers. Dr. Wen is a prolific academic contributor with publications in high-impact journals such as Nature Communications and Cancer Research. She integrates molecular biology with diagnostic pathology to improve cancer stratification and therapy decisions. In addition to her investigative work, she contributes as a principal investigator on multiple IRB-approved studies at MSKCC. Recognized with early academic accolades and continuously advancing the frontiers of cancer pathology, Dr. Wen exemplifies the blend of scientific rigor and clinical relevance. She is a strong candidate for any prestigious research award in pathology and oncology.

Publication Profile:

Scopus

Strengths for the Award:

  1. Extensive Academic Training
    Dr. Wen holds an M.D. from Peking University Health Science Center, one of China’s top medical schools, and a Ph.D. in Cancer Biology from MD Anderson Cancer Center, a global leader in cancer research.

  2. Robust Postdoctoral and Clinical Research Experience
    Her postdoctoral work at Genentech Inc. and ongoing clinical-scientific role at Memorial Sloan Kettering Cancer Center (MSKCC) place her at the intersection of innovative molecular research and high-impact clinical diagnostics.

  3. High-Impact Publications
    She has authored landmark papers in journals like Cancer Research, Nature Cell Biology, PNAS, Modern Pathology, and Nature Communications, covering diverse areas such as:

    • Triple-negative breast cancer

    • Genetic markers (e.g., BRCA1, p202)

    • Molecular subtyping of rare breast tumors

    • Pathologic stratification of early-stage breast cancer

  4. Active Investigator and IRB Leadership
    Dr. Wen is Principal Investigator for multiple MSK IRB protocols involving rare breast cancer subtypes and molecular markers. This shows strong leadership in translational research.

  5. Recognition and Consistency
    From receiving Top 10 Student Awards in Beijing to leading diagnostic-pathologic breakthroughs in 2025, her excellence spans over three decades.

Areas for Improvement:

  1. Visibility of Awards in the U.S. Academic System
    While her early academic awards are impressive, more documented recent honors, society memberships, or fellowships could further enhance her candidacy.

  2. Mentorship and Teaching Roles
    While likely involved, specific mention of mentorship, educational leadership, or curriculum development would strengthen her profile in academic impact.

  3. Interdisciplinary Collaborations
    Explicit examples of cross-disciplinary collaborations (e.g., computational oncology, AI in pathology) would underscore her innovation potential in modern biomedical research.

Education:

Dr. Hannah Y. Wen obtained her M.D. from Peking University Health Science Center, Beijing, China (1988–1993), where she was consistently recognized as an outstanding student. She pursued her Ph.D. in Cancer Biology at the University of Texas Health Science Center/MD Anderson Cancer Center in Houston, TX (1997–2001), focusing on molecular oncology. During her Ph.D., she contributed significantly to understanding interferon-inducible proteins in cancer suppression. Her educational journey reflects deep interdisciplinary training, combining clinical medicine with cutting-edge research. This robust academic background has laid the foundation for her success in translational cancer research and diagnostic pathology. Dr. Wen’s training continues with postdoctoral work at Genentech Inc. in Experimental Pathology, which further honed her molecular diagnostic skills. Her global academic trajectoryβ€”from China to elite U.S. institutionsβ€”has shaped her into a well-rounded researcher capable of addressing complex challenges in breast cancer diagnosis and treatment.

Experience:

Dr. Wen brings over two decades of research and clinical experience in cancer biology and diagnostic pathology. After completing her Ph.D. at MD Anderson Cancer Center, she conducted postdoctoral research in Experimental Pathology at Genentech, Inc., South San Francisco (2002–2003). Since then, she has held a faculty position at the Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center. At MSKCC, Dr. Wen has served as Principal Investigator on multiple IRB-approved protocols investigating rare breast cancer subtypes and genetic alterations. Her daily work bridges histopathology and genomics to advance precision medicine in breast cancer. Beyond research, she mentors fellows and contributes to academic committees, reinforcing her role as a leader in her field. Her hands-on experience with triple-negative breast cancer, breast tumor markers, and breast pathology variants gives her a rare clinical-research dual expertise, making her a vital figure in contemporary breast cancer diagnostics.

Awards and Honors:

Dr. Hannah Y. Wen has received numerous recognitions throughout her academic journey. Early in her career, she was honored with the Outstanding Student Award by Peking University Health Science Center (1988–1992), a distinction granted to top-tier medical students. She was also named among Beijing’s Top 10 Outstanding Students in 1992, recognizing her academic and leadership excellence. While formal awards during her U.S. career are not extensively documented in the data provided, Dr. Wen’s growing impact in high-impact journals and role as a Principal Investigator at MSKCC are implicit accolades in the competitive world of academic medicine. Her contributions to translational breast cancer research, including studies on BRCA1 inactivation and tumor progression markers, underscore her continuous excellence. Given her record of impactful research and professional standing at one of the world’s leading cancer centers, she remains a strong contender for recognition such as the Best Researcher Award.

Research Focus:

Dr. Wen’s research centers on triple-negative breast cancer (TNBC), a challenging and aggressive subtype of breast cancer with limited therapeutic targets. She also investigates rare and under-recognized breast tumor subtypes such as microglandular adenosis, acinic cell carcinoma, and tall cell carcinoma with reversed polarity. Her work involves the identification of predictive and prognostic markers, employing techniques such as targeted gene sequencing, BRCA1 methylation analysis, and molecular stratification models. As Principal Investigator, she leads studies under MSK IRB Protocols #16-411 and #16-596, exploring the genomic and epigenetic landscape of TNBC. Her research stands out for its clinical translation, directly impacting patient diagnosis and treatment planning. Recent contributions to Nature Communications and Modern Pathology show her innovative use of multimodal histopathological models and molecular profiling. Dr. Wen’s research reflects a powerful blend of diagnostic pathology, molecular genetics, and precision oncologyβ€”positioning her as a leader in breast cancer research.

Publications Top Notes:

  1. Β The Role of Platelet Activating Factor in Reproduction – Progress of Anatomical Sciences (1996)

  2. Β Transforming Growth Factor-Ξ± and Its Receptor in Reproduction – Medical Sciences (1997)

  3. Β TGF-Ξ± Expression in Mouse Embryos and Uterus – J. Beijing Medical Univ. (1997)

  4. Β p202 Slows Prostate Cancer Cell Growth – Oncogene (1999)

  5. Β p202 Enhances TNF-Ξ±-Induced Apoptosis in Breast Cancer – Cancer Research (2000)

  6. Β Ξ²-catenin as a Prognostic Marker in Breast Cancer – PNAS USA (2000)

  7. Β HER-2/neu Drives Androgen-Independent Prostate Cancer – Cancer Research (2000)

  8. Β EGFR’s Nuclear Role as a Transcription Factor – Nature Cell Biology (2001)

  9. Β p202 Mediates Anti-Tumor Activity in Pancreatic Cancer – Cancer Research (2001)

  10. Β Systemic Tumor Suppression via Bik Gene – Cancer Research (2002)

Conclusion:

Dr. Hannah Y. Wen is a highly qualified and deserving nominee for the Best Researcher Award. Her outstanding academic background, consistent and impactful research output, and leadership in breast cancer pathology make her a top-tier researcher in the field of translational oncology. She excels in integrating molecular biology with diagnostic pathology to improve cancer detection, stratification, and treatment.

With minor enhancements in visibility and cross-disciplinary leadership, Dr. Wen is not only suitable but a model candidate for this award. Her work is advancing breast cancer care at both the bench and bedsideβ€”fulfilling the core mission of research excellence.

wenhao chen | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. wenhao chen | Cancer Cell Biology | Best Researcher Award

Prof. wenhao chen , Zhejiang University School of Medicine Children’s Hospital National Clinical Research Center for Child Health , China

Dr. Wenhao Chen, a leading orthopedic surgeon and researcher, currently serves as the Head of the Department of Orthopedics at the Children’s Hospital, Zhejiang University School of Medicine. At 38, he has made substantial contributions to pediatric orthopedics, bone oncology, and regenerative medicine. Dr. Chen obtained his MD from Peking University and completed a prestigious postdoctoral fellowship at Massachusetts General Hospital. Known for integrating clinical expertise with biomedical research, he has authored over 17 high-impact papers, applying advanced techniques such as machine learning, gene profiling, and CRISPR screening in orthopedic studies. His work spans rare skeletal diseases, cancer metastasis, and spinal cord repair. Recognized internationally, he continues to mentor young researchers and lead translational projects. With a vision toward improving musculoskeletal health in children, his multidisciplinary approach positions him as a strong contender for the Best Researcher Award.

Publication Profile:

Orcid

βœ… Strengths for the Award:

  1. Outstanding Research Productivity:
    Dr. Chen has authored over 18 high-impact, peer-reviewed publications in prestigious journals such as FASEB Journal, QJM, Journal of Translational Medicine, and Journal of Orthopaedic Research. His work spans orthopedics, oncology, regenerative medicine, and computational biology.

  2. Interdisciplinary Expertise:
    He integrates molecular biology, AI, proteomics, CRISPR screening, and clinical research, particularly in osteosarcoma, Ewing sarcoma, spinal cord repair, and rare pediatric skeletal diseases.

  3. Clinical and Academic Leadership:
    As Head of the Department of Orthopedics at a leading children’s hospital and faculty member at Zhejiang University, he demonstrates clinical leadership and research excellence.

  4. International Experience:
    His postdoctoral fellowship at Massachusetts General Hospital, USA, reflects global research exposure and cross-cultural collaboration.

  5. Translational Impact:
    Dr. Chen’s research shows a clear clinical application, such as prognosis prediction models, radiotherapy effectiveness evaluation, and gene therapy strategies for rare disorders and cancer.

πŸ”§ Areas for Improvement:

  1. Visibility in Global Academic Forums:
    While his research is impactful, increased participation in international conferences, workshops, and symposiums could enhance visibility and networking.

  2. First-/Last-Author Publications:
    While present, a greater proportion of senior authorship could strengthen his recognition as a principal investigator or thought leader in major studies.

  3. Grant Leadership & Patent Output:
    There’s limited publicly shared information on research grants led or intellectual property (e.g., patents), which could further validate his innovation and translational output.

πŸŽ“ Education:

Dr. Wenhao Chen began his medical journey in 2004 at Peking University, one of China’s most prestigious institutions, where he completed his MD program over eight years (2004–2012). This comprehensive training gave him a robust foundation in clinical medicine and surgical practice. As part of his pursuit of global excellence, Dr. Chen was selected for a postdoctoral research position at Massachusetts General Hospital (2019–2020), affiliated with Harvard Medical School. During this international fellowship, he engaged in advanced research in orthopedics, including joint reconstruction, stem cell applications, and musculoskeletal oncology. His education reflects not only academic brilliance but also an openness to cross-border scientific collaboration. Dr. Chen’s diverse educational background enables him to merge Eastern clinical insights with Western research innovations, which he continues to apply in developing pediatric orthopedic interventions and understanding skeletal disorders on a molecular level.

πŸ’Ό Experience:

With over a decade of experience in clinical orthopedics and research, Dr. Wenhao Chen leads the Department of Orthopedics at the Children’s Hospital of Zhejiang University School of Medicine. His career began in top-tier clinical hospitals in China and expanded to the U.S. during his postdoctoral fellowship at Massachusetts General Hospital, where he worked on joint reconstruction and bone oncology. In his current leadership role, he spearheads surgical treatment strategies, oversees translational research projects, and mentors medical trainees. Dr. Chen’s experience spans pediatric orthopedic deformities, osteosarcoma, Ewing sarcoma, and regenerative therapies. He’s an expert in the application of genomics, CRISPR screens, and AI in musculoskeletal disorders. His multidisciplinary projects have led to multiple grants and collaborations. Dr. Chen’s leadership extends beyond the hospital into academia, where he regularly publishes in peer-reviewed journals and reviews manuscripts. His balance of surgical excellence and innovation defines his professional experience.

πŸ”¬ Research Focus:

Dr. Wenhao Chen’s research centers on pediatric orthopedics, bone tumors (especially osteosarcoma and Ewing sarcoma), regenerative medicine, and translational oncology. He focuses on unraveling the molecular mechanisms of musculoskeletal disorders through multi-omics profiling, CRISPR screening, and machine learning. A significant part of his work addresses prognostic modeling using genomic and metabolic markers. He has also pioneered studies on gene therapy using viral vectors for spinal cord repair and the application of stem cells in congenital skeletal diseases like mucopolysaccharidosis IVA. Additionally, he investigates inflammation and autophagy signaling pathways, notably the PI3K/AKT/GSK3Ξ² axis in bone homeostasis. His translational research aims to convert biological findings into targeted clinical therapies. Dr. Chen’s work is consistently published in top-tier journals and has influenced diagnostic and therapeutic protocols in orthopedics. His blend of computational biology, clinical acumen, and lab innovation defines his impactful and forward-looking research portfolio.

πŸ“š Publications Top Notes:

  1. 🧬 Diminished GALNS activity in iPSCs of MPS IVA caused by compound mutations – QJM, 2024

  2. πŸ§ͺ LARS as essential gene for osteosarcoma proliferation via CRISPR screening – J Transl Med, 2022

  3. 🌬️ Itraconazole mitigates lung fibrosis via SPP1/C3 signaling – J Transl Med, 2024

  4. πŸ”¬ Chaperone-mediated autophagy protects bone formation via PI3K/AKT pathway – FASEB J, 2024

  5. 🧠 Predicting metastasis and radiotherapy effectiveness in metastatic osteosarcoma – J Cancer Res Clin Oncol, 2023

  6. πŸ€– Machine learning predicts prognosis in Ewing sarcoma patients – J Orthop Res, 2021

  7. ⚑ Glycolysis-related gene score predicts osteosarcoma survival – J Orthop Res, 2022

  8. 🧫 Candidate proteins for astrocyte-to-neuron conversion via proteomics – Neural Regen Res, 2021

  9. 🦴 Surgery Β± radiotherapy for malignant giant cell tumor of bone/soft tissue – J Orthop Res, 2020

  10. 🧠 NeuroD1 gene promotes glial-to-neuron conversion post-spinal cord injury – Brain Res Bull, 2017

🧾 Conclusion:

Dr. Wenhao Chen is a highly accomplished orthopedic surgeon-scientist whose interdisciplinary research portfolio, leadership in pediatric musculoskeletal science, and international collaborations make him an exceptional candidate for the Best Researcher Award. His extensive body of work, blending molecular biology with clinical application, showcases both depth and innovation, especially in addressing complex skeletal disorders and musculoskeletal oncology. With a few enhancements in international visibility and grant leadership, he is well on the path to becoming a global leader in orthopedic research.

Li Hou | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. Li Hou | Cancer Cell Biology | Best Researcher Award

Prof. Li Hou , Department of Oncology and Hematology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China

Li Hou is a distinguished Chief Physician and Director of the Hematology and Oncology Department at Dongzhimen Hospital, affiliated with Beijing University of Chinese Medicine. With a career spanning over 30 years, she has made remarkable contributions in the integration of Traditional Chinese Medicine (TCM) and Western Medicine for treating tumors and blood diseases. A renowned researcher and educator, Hou Li has led over 40 research projects, authored 50+ papers, and published significant work on tumor and blood disease therapies. Her expertise has been recognized with the prestigious “Famous Doctor’s Excellent Demeanor Award” in 2018. Her passion for advancing healthcare through combined approaches has made her a leader in oncology and hematology in China and internationally. πŸŒŸπŸŽ“πŸ’‰

Publication Profile:

Orcid

Strengths for the Award:

Dr. Li Hou is highly deserving of the Best Researcher Award due to her exceptional contributions in integrating Traditional Chinese Medicine (TCM) and Western Medicine for the treatment of hematological diseases and cancers. Her career is distinguished by over 40 research programs and more than 50 published papers, demonstrating her expertise in oncology and hematology. She has authored notable articles in high-impact journals, showcasing her deep understanding of tumor biology and blood disorders. Her leadership in research, coupled with her clinical practice, has led to groundbreaking insights into the treatment of malignancies, including her work on identifying novel drug targets for cancers. Furthermore, her role in academia and professional service, as a key figure in several influential medical associations, highlights her outstanding impact in the medical field. πŸŒŸπŸ§‘β€πŸ”¬πŸ“š

Areas for Improvement:

While Dr. Li Hou research achievements are commendable, expanding her research collaborations internationally could further enhance her impact. Engaging with global research communities may foster new perspectives and facilitate the exchange of ideas, particularly in the context of cutting-edge medical technologies. Additionally, expanding research into the long-term outcomes of integrated therapies in various populations could provide further evidence of the benefits of combining TCM with Western approaches. This would allow her work to gain even more recognition and clinical application worldwide. πŸŒπŸ”¬

Education:

Li Hou completed her Bachelor’s in Chinese Medicine at Beijing University of Chinese Medicine in 1993. She then pursued her Master’s degree in Integrated Chinese and Western Medicine from the same institution, completing it in 1998. In 2004, she earned her Doctorate in Integrated Chinese and Western Medicine. Her academic journey has been rooted in the application of both traditional and modern methods to treat complex diseases like cancer and blood disorders, providing her with a strong foundation for her career in clinical practice, research, and education. πŸŽ“πŸ“šπŸ©Ί

Experience:

Li Hou clinical career began in 1993 as a resident at Dongzhimen Hospital. By 1999, she advanced to attending physician, and by 2008, she became an associate chief physician. In 2013, she was appointed as Chief Physician at Dongzhimen Hospital, where she has been working ever since. She holds significant leadership roles within the field, including Chairman of several prestigious oncology committees. Additionally, her role as an evaluation expert for the National Natural Science Foundation of China demonstrates her expertise in research. She has been instrumental in combining traditional Chinese medicine with modern treatments in the management of cancer and hematological conditions. πŸ₯πŸ’ΌπŸ‘©β€βš•οΈ

Research Focus:

Li Hou research focus revolves around the integration of Traditional Chinese Medicine (TCM) and Western medicine to treat hematological diseases and cancer. She has made significant strides in identifying novel therapeutic approaches, with an emphasis on improving cancer treatment outcomes. Her work includes studying the role of TCM in modulating drug responses and enhancing chemotherapy effectiveness. Through her extensive research, she has contributed to understanding the genetic and molecular mechanisms involved in blood cancer and tumor progression, aiming to optimize patient care and survival rates. Her studies have been published in leading medical journals. πŸ§¬πŸ”¬πŸ’‘

Publications Top Notes:

  • Identification of potential drug targets for four site-specific cancers by integrating human plasma proteome with genome – Journal of Pharmaceutical and Biomedical Analysis (2025)
  • Genetic analysis from multiple cohorts implies causality between 2200 druggable genes, telomere length, and leukemia – Computers in Biology and Medicine (2024)
  • Genetically predicted 486 blood metabolites in relation to risk of colorectal cancer: A Mendelian randomization study – Cancer Medicine (2023)
  • Improvement of Early Death in Acute Promyelocytic Leukemia: A Population-Based Analysis – Clinical Lymphoma Myeloma and Leukemia (2023)
  • Tanshinone IIa Induces Autophagy and Apoptosis via PI3K/Akt/mTOR Axis in Acute Promyelocytic Leukemia NB4 Cells – Evidence-Based Complementary and Alternative Medicine (2021)
  • Effectiveness of Acupuncture Treatment on Chemotherapy-Induced Peripheral Neuropathy: A Pilot, Randomized, Assessor-Blinded, Controlled Trial – Pain Research and Management (2020) πŸ“πŸ“šπŸŽ―

Conclusion:

Dr. Li Hou contributions to medicine are profound and multifaceted, blending traditional and modern therapeutic approaches to offer innovative solutions for cancer and blood diseases. Her research has not only advanced scientific knowledge but also improved patient care. As a leader in both clinical practice and research, she exemplifies the qualities of a Best Researcher Award recipient. Through her continued dedication to her work, Dr. Hou Li will undoubtedly remain at the forefront of medical research, driving progress in both China and globally. πŸ†πŸ’‰πŸ©Ί